---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/271136392.md"
description: "The Nasdaq Biotechnology Index fell by more than 1%. Among the constituent stocks, Lyell Immunopharma dropped 11.28%, Vor Biopharma fell 8.16%, Alumis decreased 6.99%, and Oruka Therapeutics declined 7.93%. Meanwhile, Coherus BioSciences rose 6.34%, Pyxis Oncology increased 8.02%, Ultragenyx Pharmaceutical gained 13.59%, and Jyong Biotech surged 43.38%"
datetime: "2025-12-30T19:31:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/271136392.md)
  - [en](https://longbridge.com/en/news/271136392.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/271136392.md)
generator: "portal-rs"
---

# 

The Nasdaq Biotechnology Index fell over 1%. Component stocks Lyell Immunopharma dropped 11.28%, Vor BioPharma fell 8.16%, Alumis decreased 6.99%, and Oruka Therapeutics was down 7.93%, currently ranking fourth from the bottom. Coherus BioSciences rose 6.34%, Pyxis Oncology increased 8.02%, Ultragenyx Pharmaceutical climbed 13.59%, and Jyong Biotech surged 43.38%

### Related Stocks

- [LYEL.US](https://longbridge.com/en/quote/LYEL.US.md)
- [PYXS.US](https://longbridge.com/en/quote/PYXS.US.md)
- [ALMS.US](https://longbridge.com/en/quote/ALMS.US.md)
- [VOR.US](https://longbridge.com/en/quote/VOR.US.md)

## Related News & Research

- [GRAPHIC-Take Five: AI trade meets the Fed](https://longbridge.com/en/news/302836715.md)
- [U.S. oil exports to Asia plunge as war disrupts shipping, lifting tanker rates to record high](https://longbridge.com/en/news/302792281.md)
- [Iran Is 'Doing Everything They Can to Drive Up' Oil Prices, Says Trump](https://longbridge.com/en/news/302765449.md)
- [Western Digital Q1 Revenue Surges 55% YoY, Shares Drop Nearly 7%: Can $330 Support Hold?](https://longbridge.com/en/news/302840204.md)
- [This market signal just occurred for only the second time since 1999. Here's what happened and what it means.](https://longbridge.com/en/news/302851124.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**